Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis

  • Authors:
    • Emiko Hayashi
    • Yutaka Motomura
    • Hirofumi Shirakawa
    • Toshiaki Yoshikawa
    • Nobuyuki Oba
    • Shuta Nishinakagawa
    • Yasuhiro Mizuguchi
    • Tatsuya Kojima
    • Kazuhiro Nomura
    • Tetsuya Nakatsura
  • View Affiliations

  • Published online on: July 1, 2009     https://doi.org/10.3892/or_00000418
  • Pages: 149-154
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glypican-3 (GPC3) is one of carcinoembryonic antigens known to be overexpressed in hepatocellular carcinoma (HCC). It has been suggested that GPC3 may be related to the development of HCC in a background of chronic hepatitis (CH) and liver cirrhosis (LC). Therefore, in an attempt to establish an early diagnostic marker of HCC, we quantified the number of GPC3-specific CTLs in the peripheral blood of CH and LC patients. We selected CH and LC patients who were HCV-RNA (+) or HBs antigen (+) within 6 months prior to the study and had no HCC nodules as detected by imaging. A total of 56 patients with CH and LC, and 45 patients with HLA-A24+ or HLA-A2+ were enrolled for this investigation. After isolation of mononuclear cells from each patient's peripheral blood specimens, we performed ELISPOT assay using HLA-A24- and HLA-A2-restricted GPC3 peptides. In the ELISPOT assay, GPC3-specific CTLs were detected in 10 of the 45 CH and LC cases (22%). In addition, the plasma titers of anti-GPC3 IgG were increased in the CH and LC patients as compared with those in healthy donors. GPC3-specific CTLs were found to be present not only in patients with HCC, but also in patients with CH and LC. This suggests the possibility of GPC3-specific CTLs serving as a marker for the early diagnosis of imaging-invisible HCC.

Related Articles

Journal Cover

July 2009
Volume 22 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hayashi E, Motomura Y, Shirakawa H, Yoshikawa T, Oba N, Nishinakagawa S, Mizuguchi Y, Kojima T, Nomura K, Nakatsura T, Nakatsura T, et al: Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. Oncol Rep 22: 149-154, 2009.
APA
Hayashi, E., Motomura, Y., Shirakawa, H., Yoshikawa, T., Oba, N., Nishinakagawa, S. ... Nakatsura, T. (2009). Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. Oncology Reports, 22, 149-154. https://doi.org/10.3892/or_00000418
MLA
Hayashi, E., Motomura, Y., Shirakawa, H., Yoshikawa, T., Oba, N., Nishinakagawa, S., Mizuguchi, Y., Kojima, T., Nomura, K., Nakatsura, T."Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis". Oncology Reports 22.1 (2009): 149-154.
Chicago
Hayashi, E., Motomura, Y., Shirakawa, H., Yoshikawa, T., Oba, N., Nishinakagawa, S., Mizuguchi, Y., Kojima, T., Nomura, K., Nakatsura, T."Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis". Oncology Reports 22, no. 1 (2009): 149-154. https://doi.org/10.3892/or_00000418